Skip to main content

Table 2 Treatment and outcome of control and HA group (Cytosorb™-group)

From: Adsorption therapy in critically ill with septic shock and acute kidney injury: a retrospective and prospective cohort study

Outcome measure Control group (N = 33) Cytosorb™-group (N = 43) p value
ICU mortality rate 66.7% (22/33) 72.1% (31/43)  
O/E ratio ICU mortality 0.81 (0.65–0.94) 0.82 (0.72–0.93)  
Hospital mortality rate 66.7% (22/33) 76.7% (33/43)  
O/E ratio hospital-mortality 0.81 (0.65–0.94) 0.88 (0.77–0.99)  
LOS ICU (days [d]) 21 (6, 54) 12 (3, 23) 0.026
LOS ICU for survivors (d) [N = 11 vs 12] 64 (45, 80) 29 (20, 40) 0.006
LOS ICU for non-survivors (d), [N = 22 vs 31] 10 (4, 20) 7 (3, 14) 0.115
LOS hospital (d) 25 (11,71) 15 (5,30) 0.040
LOS hospital survivors (d) 86 (68, 122) 52 (38, 45) 0.004
LOS hospital non-survivors (d) 13 (5, 28) 8 (5, 17) 0.096
Length of ventilatory support (d) 19 (5, 41) 8 (3,17) 0.009
Length of ventilatory support for survivors (d) 42 (37, 72) 20 (11, 26) 0.001
Length of ventilatory support non-survivors (d) 10 (4, 20) 6 (3, 13) 0.121
Length of CVVHDF (d) 6 (3, 16) 3 (2, 7) 0.012
Length of CVVHDF survivors (d) 12 (4, 19) 6 (3, 10) 0.260
Length of CVVHDF non-survivors (d) 4 (2, 10) 2 (2, 4) 0.047
Length of catecholamine administration (d) 18 (7, 30) 8 (3, 13) 0.001
Length of catecholamine administration survivors (d) 29 (21, 47) 10 (7, 12) > 0.001
Length of catecholamine administration non-survivors (d) 11 (4, 20) 7 (3, 13) 0.043
  1. ICU intensive care unit, CVVHDF continuous veno-venous haemodiafiltration
\